

Shinji Urakami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8978249/publications.pdf>

Version: 2024-02-01

22
papers

447
citations

840119

11
h-index

794141

19
g-index

23
all docs

23
docs citations

23
times ranked

664
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer. <i>Anticancer Research</i> , 2020, 40, 5295-5299.	0.5	6
2	Macroscopic hematuria caused by running-induced traumatic bladder mucosal contusions. <i>IJU Case Reports</i> , 2019, 2, 27-29.	0.1	5
3	Effect of tadalafil add-on therapy in patients with persistent storage symptoms refractory to 5 α -reductase inhibitor monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 109-114.	0.6	6
4	Recent advances in medical therapy for metastatic urothelial cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 599-607.	1.0	30
5	Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening. <i>International Journal of Urology</i> , 2018, 25, 151-156.	0.5	29
6	Editorial Comment to Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes. <i>International Journal of Urology</i> , 2016, 23, 158-159.	0.5	0
7	Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1198-1202.	1.0	1
8	Patient-perceived Satisfaction After Definitive Treatment for Men With High-risk Prostate Cancer: Radical Prostatectomy vs Intensity-modulated Radiotherapy With Androgen Deprivation Therapy. <i>Urology</i> , 2015, 85, 407-414.	0.5	12
9	Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1171-1178.	1.0	22
10	Decreased incidence of skeletal-related events in mRCC. <i>Nature Reviews Urology</i> , 2014, 11, 193-194.	1.9	6
11	The Processus Vaginalis Transection Method to Prevent Postradical Prostatectomy Inguinal Hernia: Long-term Results. <i>Urology</i> , 2014, 83, 247-252.	0.5	16
12	Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 35.e1-35.e7.	0.8	3
13	Significance of zoledronic acid on survival in patients with bone metastases from renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 374-374.	0.8	0
14	Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. <i>BJU International</i> , 2012, 110, 1478-1484.	1.3	28
15	Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Prostate Cancer Patients with a Preoperative Serum PSA Level >100 ng/ml. <i>Urologia Internationalis</i> , 2011, 87, 175-181.	0.6	5
16	Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade. <i>International Urology and Nephrology</i> , 2008, 40, 365-368.	0.6	8
17	WS1-1-2 Wnt-antagonist Family Genes as Biomarkers for Diagnosis, Staging and Prognosis of Renal Cell Carcinoma Using Tumor and Serum DNA (Renal Cell Cancer). <i>Japanese Journal of Urology</i> , 2008, 99, 142.	0.0	0
18	Phase-II Study of Docetaxel, Estramustine Phosphate, and Carboplatin in Patients with Hormone-Refractory Prostate Cancer. <i>European Urology</i> , 2007, 51, 1252-1258.	0.9	25

#	ARTICLE	IF	CITATIONS
19	Bcl-2 Expression as a Predictive Marker of Hormone-Refractory Prostate Cancer Treated with Taxane-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 6116-6124.	3.2	142
20	Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot study. <i>Urology</i> , 2005, 65, 543-548.	0.5	22
21	Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate Cancer. <i>Journal of Urology</i> , 2002, 168, 2444-2450.	0.2	64
22	Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. <i>Journal of Urology</i> , 2002, 168, 2444-50.	0.2	17